http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Vyant Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
-
Vyant Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
-
Vyant Bio Reports Third Quarter 2022 Results and Provides Strategic and Business Highlights
-
Vyant Bio Reports Third Quarter 2022 Results and Provides Strategic and Business Highlights
-
Vyant Bio Presents Key Takeaways from Platform and Poster Presentations at the 2022 CDKL5 Forum Hosted by the Loulou Foundation
-
Vyant Bio Presents Key Takeaways from Platform and Poster Presentations at the 2022 CDKL5 Forum Hosted by the Loulou Foundation
-
Vyant Bio to Participate at Neuroscience 2022, the 52nd Annual Gathering of the Society for Neuroscience, on November 12-16
-
Vyant Bio to Participate at Neuroscience 2022, the 52nd Annual Gathering of the Society for Neuroscience, on November 12-16
-
Vyant Bio Teams Up with the International Rett Syndrome Foundation to Host Local Viewing Party in Honor of the 3rd Annual ‘Raise a Glass for Rett Gala’
-
Vyant Bio Teams Up with the International Rett Syndrome Foundation to Host Local Viewing Party in Honor of the 3rd Annual ‘Raise a Glass for Rett Gala’
-
Reaction Biology and Vyant Bio Announce Closing of Definitive Agreement to Acquire U.S. Operations of Vyant Bio, Inc. Subsidiary
-
Reaction Biology and Vyant Bio Announce Closing of Definitive Agreement to Acquire U.S. Operations of Vyant Bio, Inc. Subsidiary
-
Vyant Bio (VYNT) Announces 1-for-5 Reverse Stock Split
-
Vyant Bio Announces One-for-Five Reverse Stock Split
-
Vyant Bio Announces One-for-Five Reverse Stock Split
-
Vyant Bio Announces Participation at the 2022 CDKL5 Forum Hosted by the Loulou Foundation on November 7-8, 2022
-
Vyant Bio Announces Participation at the 2022 CDKL5 Forum Hosted by the Loulou Foundation on November 7-8, 2022
-
Vyant Bio to Present at the LD Micro Main Event XV on Wednesday, October 26, 2022
-
Vyant Bio to Present at the LD Micro Main Event XV on Wednesday, October 26, 2022
-
Vyant Bio to Deliver a Live Presentation at the Skyline Signature Series™ on Thursday, September 8, 2022
-
Vyant Bio to Deliver a Live Presentation at the Skyline Signature Series™ on Thursday, September 8, 2022
-
Vyant Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference
-
Vyant Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference
-
Vyant Bio Reports Second Quarter and First Half 2022 Results and Provides Strategic and Business Highlights
-
Vyant Bio Reports Second Quarter and First Half 2022 Results and Provides Strategic and Business Highlights
-
Vyant Bio Announces Rescheduled Investor Conference Call and Webcast for the Second Quarter and First Half of 2022
-
Vyant Bio Announces Rescheduled Investor Conference Call and Webcast for the Second Quarter and First Half of 2022
-
Vyant Bio Postpones Second Quarter Investor Conference Call and Webcast
-
Vyant Bio Postpones Second Quarter Investor Conference Call and Webcast
-
Vyant Bio Announces Investor Conference Call and Webcast for the Second Quarter and First Half of 2022
-
Vyant Bio Announces Investor Conference Call and Webcast for the Second Quarter and First Half of 2022
-
Vyant Bio Retains Skyline Corporate Communications Group, LLC to Provide Investor Relations Services
-
Vyant Bio Retains Skyline Corporate Communications Group, LLC to Provide Investor Relations Services
-
Vyant Bio Announces Participation in BioNJ’s 12th Annual BioPartnering Conference
-
Vyant Bio Announces Participation in BioNJ’s 12th Annual BioPartnering Conference
-
Vyant Bio Reports Fourth Quarter and Year-End 2021 Results and Provides Strategic and Business Highlights
-
Vyant Bio Reports Fourth Quarter and Year-End 2021 Results and Provides Strategic and Business Highlights
-
Vyant Bio (VYNT) and OrganoTherapeutics Announce Strategic Collaboration to Discover Therapeutics to Treat Parkinson’s Disease
-
Vyant Bio and OrganoTherapeutics Announce Strategic Collaboration to Discover Therapeutics to Treat Parkinson’s Disease
-
Vyant Bio and OrganoTherapeutics Announce Strategic Collaboration to Discover Therapeutics to Treat Parkinson’s Disease
-
Vyant Bio Announces Investor Conference Call and Webcast for the Year-End 2021
-
Vyant Bio Announces Investor Conference Call and Webcast for the Year-End 2021
-
Vyant Bio (VYNT) Issues Letter to Shareholders
-
Vyant Bio Issues Letter to Shareholders
-
Vyant Bio to Present at the H.C. Wainwright Bioconnect Conference
-
Vyant Bio to Present at the H.C. Wainwright Bioconnect Conference
-
Vyant Bio Reports Third Quarter 2021 Results and Provides Strategic Business Updates
-
Vyant Bio Reports Third Quarter 2021 Results and Provides Strategic Business Updates
-
Vyant Bio Reports Second Quarter 2021 Results and Provides Strategic Business Updates
-
Vyant Bio Reports Second Quarter 2021 Results and Provides Strategic Business Updates

